The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study
Open accessAbstract
BACKGROUND: The Coalition for Epidemic Preparedness Innovations was established in 2016, to develop vaccines that can contribute to preparedness for outbreaks of epidemic infectious diseases. Evidence on vaccine development costs for such diseases is scarce. Our goal was to estimate the minimum cost for achieving vaccine research and development preparedness targets in a portfolio of 11 epidemic infectious diseases, accounting for vaccine pipeline constraints and uncertainty in research and development preparedness outcomes. METHODS: We assembled a pipeline of 224 vaccine candidates from preclinical through to phase 2 for 11 priority epidemic infectious diseases. We used a linear regression model to identify drivers of development costs from preclinical through to end of phase 2a. Drawing from published estimates of vaccine research and development probabilities of success, we simulated costs for advancing these 224 vaccine candidates through to the end of phase 2a. We combined these findings to determine minimum costs for progressing at least one vaccine through to the end of phase 2a per epidemic infectious disease by means of a stochastic optimisation model. FINDINGS: The cost of developing a single epidemic infectious disease vaccine from preclinical trials through to end of phase 2a is US$31-68 million (US$14-159 million range), assuming no risk of failure. We found that previous licensure experience and indirect costs are upward drivers of research and development costs. Accounting for probability of success, the average cost of successfully advancing at least one epidemic infectious disease vaccine through to the end of phase 2a can vary from US$84-112 million ($23 million-$295 million range) starting from phase 2 to $319-469 million ($137 million-$1·1 billion range) starting from preclinical. This cost includes the cumulative cost of failed vaccine candidates through the research and development process. Assuming these candidates and funding were made available, progressing at least one vaccine through to the end of phase 2a for each of the 11 epidemic infectious diseases would cost a minimum of $2·8-3·7 billion ($1·2 billion-$8·4 billion range). INTERPRETATION: Our analysis provides new evidence on vaccine research and development pipelines and associated costs for 11 epidemic infectious diseases, highlighting both funding needs and research and development gaps for achieving vaccine research and development preparedness targets. FUNDING: This work was partly supported by the Research Council of Norway through the Global Health and Vaccination Programme GLOBVAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585
Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, W. J., Egger, M., Carroll, M. W., Dean, N. E., Diatta, I., Doumbia, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32621-6 · Cited by 1,110
Self-citationEstimating The Cost Of New Drug Development: Is It Really $802 Million?
Adams, C. P., & Brantner, V. V. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.420 · Cited by 907
Cost of innovation in the pharmaceutical industry
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90001-4 · Cited by 754
The cost of biopharmaceutical R&D: is biotech different?
DiMasi, J. A., & Grabowski, H. G. (2007) · Managerial and Decision Economics · doi:10.1002/mde.1360 · Cited by 517
The cost of drug development: A systematic review
Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C., & Greyson, D. (2011) · Health Policy · doi:10.1016/j.healthpol.2010.12.002 · Cited by 510
The complexity and cost of vaccine manufacturing – An overview
Plotkin, S., Robinson, J. M., Cunningham, G., Iqbal, R., & Larsen, S. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.06.003 · Cited by 434
Self-citation
Cited by
Developing Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Infectious Disease Threats in the Twenty-First Century: Strengthening the Global Response
Bloom, D. E., & Cadarette, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00549 · Cited by 806
Impact of Vaccines; Health, Economic and Social Perspectives
Rodrigues, C. M. C., & Plotkin, S. A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01526 · Cited by 737
Gender equality in science, medicine, and global health: where are we at and why does it matter?
Shannon, G., Jansen, M., Williams, K., Cáceres, C., Motta, A., Odhiambo, A., Eleveld, A., & Mannell, J. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33135-0 · Cited by 534
Emerging treatment strategies for COVID-19 infection
Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Korompoki, E., Fotiou, D., Migkou, M., Tzanninis, I.-G., Psaltopoulou, T., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00671-y · Cited by 326
Metadata
- Authors
- Gouglas, D., Thanh Le, T., Henderson, K., Kaloudis, A., Danielsen, T., Hammersland, N. C., Robinson, J. M., Heaton, P. M., & Røttingen, J.-A.
- Venue
- The Lancet Global Health
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 6
- Issue
- 12
- Pages
- e1386-e1396
- ISSN
- 2214-109X (ISSN-L)
- OpenAlex
- W2897492290
- Cited by
- 280
- References
- 28
- FWCI
- 66.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. https://app.cochat.ai/papers/10.1016/s2214-109x(18)30346-2
- The paper
- Gouglas, D., Thanh Le, T., Henderson, K., Kaloudis, A., Danielsen, T., Hammersland, N. C., Robinson, J. M., Heaton, P. M., & Røttingen, J.-A. (2018). Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(18)30346-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.